With Ryan Corcoran’s lab , we present “Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in GI cancers,” out today in #IBMpartnership #cancerresearch
Excited for our #ctDNA work in #GICancers in amazing tour de force effort resistance is the norm and #liquidbiopsy may be preferred modality of assessment compared to tissue
This systematic comparison of ctDNA vs tissue sequencing by Ryan Corcoran, Gad Getz & cols. shows the superiority of liquid biopsy for capturing clinically relevant alterations mediating therapy resistance in #Cancer patients #PrecisionMedicine #Genomics
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in GI cancers
Advantage of liquid vs tissue biopsy: detecting resistance alterations not found in the matched tumor biopsy in 78% of cases. Liquid vs tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers | Nature Medicine
#Liquidbiopsy versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal #cancers
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers | Nature Medicine
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers | Nature Medicine ⁦
6 words not often seen in top tier journals: "These findings have profound therapeutic implications ...and highlight the potential advantages of cfDNA [liquid biopsy] over tissue biopsy in the setting of acquired [#cancer] resistance.
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in #gastrointestinal #cancers